Gore Cardioform atrial septal occluder: Deployment procedure and techniques for closing challenging secundum atrial septal defects

Varun Aggarwal, Arjun K. Mohan, John L Bass, Julia Steinberger, Sameh M Said, Athar M. Qureshi

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Ostium secundum atrial septal defects are mostly closed in the cardiac catheterisation laboratories using either Amplatzer® (Abbott Laboratories, IL) atrial septal occluder, Gore® Cardioform septal occluder and more recently using the recently approved (US FDA approval June 2019) Gore® Cardioform atrial septal defect occluder (W. L. Gore & Associates, AZ). Similar to any new device in the market, there is a learning curve to the deployment of this device. We therefore aim to report the key features about this new Gore Cardioform atrial septal defect occluder device with special emphasis on technical aspects that can be employed during transcatheter closure of challenging ostium secundum atrial septal defects using this device.

Original languageEnglish (US)
Pages (from-to)1885-1892
Number of pages8
JournalCardiology in the young
Volume31
Issue number12
Early online dateOct 8 2021
DOIs
StatePublished - Dec 8 2021

Bibliographical note

Publisher Copyright:
© The Author(s), 2021. Published by Cambridge University Press.

Keywords

  • Atrial septal defect
  • Gore Cardioform atrial septal occluder
  • assured trial
  • transcatheter closure

Fingerprint

Dive into the research topics of 'Gore Cardioform atrial septal occluder: Deployment procedure and techniques for closing challenging secundum atrial septal defects'. Together they form a unique fingerprint.

Cite this